Taysha prices $28M public offering of 14M shares at $2.00 per share

Taysha Gene Therapies, Inc.

Offering of 14M shares at $2.00/share; net proceeds ~$25.6M (or ~$29.6M if over-allotment exercised).
Underwriter granted 30-day option to purchase up to 2.1M additional shares at $1.88/share.
Closing expected October 31, 2022; Goldman Sachs & Co. LLC is sole book-runner.
Proceeds will be used for general corporate purposes; dilution to existing shareholders.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Taysha Gene Therapies, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC (effective 2022-10-26).

Action: entry
Agreement: underwriting
Counterparty: Goldman Sachs & Co. LLC
Effective: 2022-10-26

Exact text from the filing

On October 26, 2022, Taysha Gene Therapies, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC (the “ Underwriter ”), to issue and sell 14,000,000 shares of common stock of the Company, par value $0.00001 per share (“ Common Stock ”), in an underwritten public offering pursuant to effective registration statements on Form S-3 (File No. 333-260069) and a related prospectus and prospectus supplement, in each case filed with the Securities and Exchange Commission (the “ Offering ”).

View on SEC.gov

Browse all material agreements →

Taysha Gene Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-271108

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.